

Drugs		All patients	Essential tremor	Holmes tremor	Other tremors
Family	Name				
Betablockers	Propranolol	30	24	1	5
Barbiturate	Primidone	17	15	0	2
	Phenobarbital	2	2	0	0
Anti-convulsants	Gabapentine	21	16	1	4
	Topiramate	16	12	0	4
	Zonizamide	2	2	0	0
	Levetiracetam	3	2	1	0
	Carbamazepine	2	1	1	0
	Pregabalin	1	0	1	0
	Sodium valproate	1	0	1	0
	Lamotrigine	1	0	1	0
Dopaminergic	L-dopa	19	10	6	3
	Piribedil	6	4	1	1
	Ropinirole	5	4	1	0
	Rotigotine	1	1	0	0
	Pergolide	1	0	1	0
	Bromocriptine	2	0	2	0
	Lisuride	1	0	1	0
	Apomorphine	1	0	1	0
Benzodiazepines	Clonazepam	11	6	4	1
	Others	4	4	0	0
Anticholinergic	Trihexiphenidyl	10	3	4	3
Miscellaneous	Oxtripitan	5	2	2	1
	Buspirone	5	2	3	0
	Tetrabenazine	2	0	2	0
	Amantadine	2	2	0	0
	Rasagiline	2	2	0	0
	Baclofene	3	0	3	0
	Dantrolene	2	0	2	0

Piracetam	2	1	1	0
Buflomedil	1	0	1	0
Clomipramine	1	0	1	0

Supplementary Table 1. *Per os* medications tried unsuccessfully prior to Botulinum toxin injections.

Supplementary Table 2. Doses of botulinum neurotoxin (onabotulinumtoxin A units) in the treatment of upper limb tremor, by target muscle. The data reflect all the injections performed during the entire course of the disease in each patient. The table also indicates how frequently each target muscle was treated (number of patients, and number of injection cycles).

Muscle	All patients (n=38)		Essential tremor (n=21)		Holmes tremor (n=8)	
	Number of: patients / injection cycles	Dose	Number of: patients / injection cycles	Dose	Number of: patients / injection cycles	Dose
Flexor pollicis longus	3 (7.9%) / 14 (0.5%)	7.6±2.8; 10 (4-10)	0 / 0	-	1 (12.5%) / 8 (0.7%)	10±0; 10 (10-10)
Adductor pollicis brevis	1 (2.6%) / 1 (0.03%)	10±NC; 10 (10-10)	1 (4.8%) / 1 (0.07%)	10.00±NC; 10 (10-10)	0 / 0	-
Flexor pollicis brevis	1 (2.6%) / 1 (0.03%)	5±NC; 5 (5-5)	1 (4.8%) / 1 (0.07%)	5.00±NC; 5 (5-5)	0 / 0	-
Abductor pollicis longus	3 (7.9%) / 9 (0.3%)	6.0±2.0; 6 (4-10)	2 (9.5%) / 5 (0.4%)	7.20±1.8; 7 (5-10)	0 / 0	-
Extensor pollicis longus	3 (7.9%) / 9 (0.3%)	5.7±1.6; 5 (4-8)	2 (9.5%) / 5 (0.4%)	6.80±1.1; 7 (5-8)	0 / 0	-
Extensor indicis	1 (2.6%) / 5 (0.2%)	8.3±2.3; 9.5 (5-10)	1 (4.8%) / 1 (0.07%)	5.00±NC; 5 (5-5)	1 (12.5%) / 5 (0.4%)	9.0±1.7; 10 (6-10)
Extensor digitorum	2 (5.3%) / 3 (0.1%)	15.0±8.7; 20 (5-20)	2 (9.5%) / 3 (0.2%)	15.00±8.7; 20 (5-20)	0 / 0	-
Flexor digitorum superficialis	2 (5.3%) / 4 (0.1%)	8.8±1.9; 9.5 (6-10)	1 (4.8%) / 2 (0.1%)	10.00±0; 10 (10-10)	1 (12.5%) / 2 (0.2%)	7.50±2.1; 7.5 (6-9)
Flexor digitorum profundis	2 (5.3%) / 21 (0.7%)	25.8±12.1; 20 (5-40)	0 / 0	-	1 (12.5%) / 17 (1.5%)	28.8±11.1; 20 (10-40)
Pronator quadratus	13 (34.2%) / 96 (3.2%)	21.6±10.0; 20 (10-50)	11 (52.4%) / 85 (5.9%)	21.9±10.7; 20 (10-50)	2 (25.0%) / 12 (1.0%)	19.6±4.0; 20 (15-30)
Pronator teres	29 (76.3%) / 272 (9.1%)	20.2±9.3; 20 (10-60)	19 (90.5%) / 182 (12.6%)	21.3±10.5; 20 (10-60)	4 (50.0%) / 34 (2.9%)	19.1±7.5; 20 (10-30)
Supinator	28 (73.7%) / 205 (6.8%)	18.8±8.3; 15 (5-50)	20 (95.2%) / 146 (10.1%)	19.5±9.3; 17.5 (5-50)	4 (50.0%) / 21 (1.8%)	15.0±5.0; 15 (10-25)
Extensor carpi ulnaris	27 (71.1%) / 315 (10.5%)	17.4±9.5; 15 (5-50)	17 (81.0%) / 206 (14.3%)	16.4±9.8; 15 (5-50)	4 (50.0%) / 52 (4.5%)	24.0±8.5; 25 (10-40)
Extensor carpi radialis	25 (65.8%) / 300 (10.0%)	18.1±10.0; 15 (5-50)	16 (76.2%) / 190 (13.2%)	16.39±9.38; 15 (5-50)	5 (50.0%) / 57 (4.9%)	25.4±10.3; 25 (10-50)

Muscle	All patients (n=38)		Essential tremor (n=21)		Holmes tremor (n=8)	
	Number of: patients / injection cycles	Dose	Number of: patients / injection cycles	Dose	Number of: patients / injection cycles	Dose
Flexor carpi ulnaris	29 (76.3%) / 349 (11.6%)	22.0±15.4; 20 (5-65)	16 (79.2%) / 179 (12.4%)	17.0±8.2; 15 (5-50)	5 (62.5%) / 99 (8.5%)	34.7±21.0; 25 (7.5-65)
Flexor carpi radialis	28 (73.7%) / 342 (11.4%)	23.4±15.8; 20 (5-65)	16 (76.2%) / 178 (12.3%)	17.5±8.9; 15 (5-50)	5 (62.5%) / 115 (9.9%)	35.5±19.8; 40 (7.5-65)
Brachio-radialis	7 (18.4%) / 70 (2.3%)	32.1±8.5; 30 (10-60)	2 (9.5%) / 23 (1.6%)	37.4±9.2; 40 (20-60)	3 (37.5%) / 44 (3.8%)	29.9±6.4; 30 (20-50)
Brachialis	6 (15.8%) / 59 (2.0%)	28.4±8.2; 30 (10-40)	5 (23.8%) / 32 (2.2%)	24.7±9.7; 25 (10-40)	2 (25.0%) / 29 (2.5%)	32.6±2.5; 35 (30-35)
Biceps brachialis	14 (36.8%) / 174 (5.8%)	34.9±11.7; 35 (10-80)	8 (38.1%) / 78 (5.4%)	28.4±9.6; 30 (10-50)	5 (62.5%) / 93 (8.0%)	39.2±9.8; 40 (20-60)
Triceps brachialis	10 (26.3%) / 110 (3.7%)	40.2±11.0; 40 (10-60)	4 (19.1%) / 36 (2.5%)	32.9±10.5; 30 (10-50)	5 (62.5%) / 69 (5.9%)	43.1±9.2; 40 (30-60)
Deltoideus	16 (42.1%) / 192 (6.4%)	43.6±20.0; 40 (20-150)	9 (42.9%) / 38 (2.6%)	31.3±7.6; 30 (20-40)	5 (62.5%) / 146 (12.5%)	48.2±21.4; 50 (20-150)
Pectoralis major	9 (23.7%) / 169 (5.6%)	50.9±14.7; 50 (20-100)	4 (19.1%) / 22 (1.5%)	35.9±7.5; 40 (20-50)	6 (75.0%) / 144 (12.3%)	53.4±14.3; 30 (30-100)
Dorsalis major	8 (21.1%) / 139 (4.6%)	49.5±10.8; 50 (20-85)	2 (9.5%) / 17 (1.2%)	34.4±7.5; 40 (20-40)	5 (62.5%) / 123 (10.5%)	51.4±9.5; 50 (30-85)
Trapezius	4 (10.5%) / 30 (1.0%)	41.33±8.09; 40 (25-50)	0 / 0	-	3 (37.5%) / 25 (2.1%)	42.8±7.8; 40 (25-50)
Teres major	10 (26.3%) / 40 (1.3%)	43.1±12.0; 45 (20-80)	3 (14.3%) / 5 (0.4%)	40.0±7.1; 40 (30-50)	5 (62.5%) / 33 (2.8%)	45.6±12.7; 50 (20-80)
Teres minor	9 (23.7%) / 40 (1.3%)	44.4±13.8; 40 (20-80)	3 (14.3%) / 5 (0.4%)	36.7±10.3; 40 (20-50)	5 (62.5%) / 23 (2.0%)	40.4±13.0; 40 (20-80)
Infra-spinatus	5 (13.2%) / 10 (0.3%)	36.5±6.3; 35 (30-50)	3 (14.3%) / 3 (0.2%)	33.3±5.8; 30 (30-40)	2 (25.0%) / 7 (0.6%)	37.9±6.4; 35 (30-50)
Supra-spinatus	1 (2.6%) / 9 (0.3%)	38.89±3.33; 40 (30-40)	0 / 0	-	0 / 0	-
Levator scapulae	2 (5.3%) / 15 (0.5%)	44.00±9.86; 50 (20-50)	0 / 0	-	1 (12.5%) / 10 (0.9%)	41.0±11.0; 45 (20-50)

Doses are quoted as the mean±standard deviation; median(min-max). SD: standard deviation; NC: not calculable (one injection only). The botulinum neurotoxin dose was calculated in onabotulinumtoxin A units, since the latter was used for the great majority of the injections. If another toxin was injected, the following ratios were used: incobotulinumtoxin A:onabotulinumtoxin A 1:1, abobotulinumtoxin A:onabotulinumtoxin A